U.S. Stock Market Movement | Latigo Biotherapeutics (LTGO.US) Debuts on U.S. Market, Shares Surge Over 14% After Opening

智通财经2026/08/07 16:36

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zhituo Finance APP has learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) debuted on the US stock market. As of press time, the stock had risen over 14%, trading at $20.53. Latigo is dedicated to developing non-opioid analgesics targeting the Nav1.8 sodium ion channel. Its core candidate drug, LTG-001, is an oral Nav1.8 inhibitor mainly used to treat moderate to severe acute pain, including postoperative pain. This medication aims to provide pain relief comparable to opioids while avoiding the risk of addiction. Nav1.8 is primarily expressed in peripheral pain-sensing neurons, and its inhibitor does not act on the central nervous system, thus eliminating addictive potential.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Robinhood’s crypto trading revenue in Q3 dropped 55% year-over-year to $120 million, with on-chain contributions excluded resulting in only $94 million. Robinhood Chain processed over $8 billion in DEX transactions in its first quarter, contributing $26 million in revenue. Event contract revenue reached $173 million, representing a more than sixfold year-over-year increase.

智通财经•2026/11/11 08:26